Development and Validation of a Stability Indicating RP-UPLC Method for Determination of Quetiapine in Pharmaceutical Dosage Form by Trivedi, Rakshit Kanubhai & Patel, Mukesh C.
Sci  Pharm   www.scipharm.at 
Research article  Open Access 
Development and Validation of a  
Stability Indicating RP-UPLC Method for 
Determination of Quetiapine in  
Pharmaceutical Dosage Form 
Rakshit Kanubhai TRIVEDI * 
1,2, Mukesh C. PATEL 
2 
1 Analytical Research and Development, Integrated Product Development, Dr. Reddy’s Laboratories Ltd., 
Bachupally, Hyderabad-500 072, India 
2 P. S. Science and H. D. Patel Arts College, S. V. Campus, Kadi-382 715, Gujarat, India 
* Corresponding author. E-mail: triveditr@yahoo.com (R. K. Trivedi) 
Sci Pharm. 2011; 79: 97–111        doi:10.3797/scipharm.1009-12 
Published:   January 16
th  2011    Received:    September  25
th 2010 
Accepted:   January 16
th 2011 
This article is available from: http://dx.doi.org/10.3797/scipharm.1009-12 
© Trivedi and Patel; licensee Österreichische Apotheker-Verlagsgesellschaft m. b. H., Vienna, Austria. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 
(http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction 
in any medium, provided the original work is properly cited. 
Abstract 
The present work reports a stability indicating reversed phase ultra performance 
liquid chromatography (RP-UPLC) method for the quantitative determination of 
quetiapine in pharmaceutical dosage form. The chromatographic separation is 
performed on an Agilent Eclipse Plus C18, RRHD 1.8 µm (50 mm x 2.1 mm) 
column using gradient elution. The optimized mobile phase consists of 0.1 % 
aqueous triethylamine (pH 7.2) as a solvent-A and 80:20 v/v mixture of 
acetonitrile and methanol as solvent-B. The eluted compounds are monitored at 
252 nm wavelength using a UV detector. The developed method separates 
quetiapine from its five impurities/degradation products within a run time of 5 
min. Stability indicating capability of the developed method is established by 
analyzing forced degradation samples in which the spectral purity of quetiapine 
is ascertained along with the separation of degradation products from analyte 
peak. The developed RP-UPLC method is validated as per International 
Conference on Harmonization (ICH) guidelines with respect to system 
suitability, specificity, precision, accuracy, linearity, robustness and filter 
compatibility.  
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Introduction 
Quetiapine, {2-[4-(dibenzo[b,f][1,4]thiazepin-11-yl)piperazin-1-yl]ethoxy}ethanol, is an 
atypical antipsychotic drug with a unique receptor-binding profile belonging to a new 
chemical class, the dibenzothiazepine derivatives [1–4]. Quetiapine is an antagonist at a 
broad range of neurotransmitter receptors [3, 4]. Quetiapine is used in the treatment of 
schizophrenia or manic episodes associated with bipolar disorder. These antipsychotics 
have a low incidence of extrapyramidal side effects and tardive dyskinesias compared to 
older antipsychotics. Quetiapine (Quetiapine Fumarate, Seroquel
TM) is approved by the US 
Food and Drug Administration (FDA) in 1997. The advantages of the therapeutic profile of 
quetiapine have led to increasing use in the clinical practice, which encourages the 
development of new analytical method to provide driving force in today’s pharmaceutical 
industry. Higher sample throughput with more information per sample may decrease the 
time to market, an important driving force in today’s pharmaceutical industry. UPLC is a 
new category of separation technique based upon well-established principles of liquid 
chromatography, which utilizes sub-2 µm particles for stationary phase. These particles 
operate at elevated mobile phase linear velocities to affect dramatic increase in resolution, 
sensitivity and speed of analysis. Owing to its speed and sensitivity, this technique is 
gaining considerable attention in recent years for pharmaceuticals and biomedical 
analysis. In the present work, this technology has been applied to the method 
development and validation study of assay determination of quetiapine dosage forms.  
Also, the parent drug stability test guideline Q1A (R2) issued by the International 
Conference on Harmonization (ICH) [5] suggests that stress studies should be carried out 
on a drug to establish its inherent stability characteristics, leading to identification of 
degradation products and, hence, supporting the suitability of the proposed analytical 
procedures. It also requires that analytical procedures for testing the stability of samples 
should be stability-indicating and should be fully validated. Chemical structures, IUPAC 
name and UV spectrums of quetiapine / impurities / degradation products were presented 
in Figure 1. 
A detailed literature survey for quetiapine revealed that few analytical methods are 
available using HPLC were; S. Radha Krishna et al. [6], describe stability indicating 
method for related substances of quetiapine drug substance; F. Belal et al. [7], 
demonstrated separation of two impurity from quetiapine; V. Pucci et al. [8], determination 
of quetiapine was describe with non stability indicating method. Polarographic method is 
also reported for the analysis of quetiapine in pharmaceuticals [9]. HPTLC method is also 
reported by S.R. Dhaneshwar et al. [10]. Determination of quetiapine by Capillary zone 
electrophoretic method is reported by S. Hillaert et al. [11]. A Voltammetric analysis of 
quetiapine in human serum and urine is also reported [12]. GC/MSD [13], LC-MS [14-22], 
and LC-MS-MS [23] are reported for determination of quetiapine in drug substance, 
pharmaceutical formulations and biological matrices. Identification and characterization of 
quetiapine impurities was also reported [24, 25].  
To the best of our knowledge, none of the currently available analytical methods can 
separate all the known related compounds and degradation impurities of quetiapine 
dosage form. Quetiapine pharmaceutical formulation is also not official in any 
pharmacopoeia yet. Furthermore, there is no less time-consuming and stability-indicating 
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and accurately quantify quetiapine dosage form. Also the cost of the analysis using LC-
MS, GC/MSD and LC-MS-MS is very high and also very delicate instrument are needed 
compared to UPLC with respect to routine quality control analysis. Hence, we focused on 
developing a selective, fast, cost-effective and stability-indicating method using this 
advance technique (UPLC) for the assay determination of quetiapine in solid 
pharmaceutical dosage forms.  
Hence a reproducible stability-indicating RP-UPLC method was developed which is less 
time-consuming and more selective compared to the all present methods, which takes only 
about 5 min for a single run. Thereafter, this method was successfully validated according 
to the ICH guideline [27].  
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Fig. 1.  Chemical structures, IUPAC name and UV spectrums of quetiapine / impurities / 
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Fig. 1.  (Cont.) 
Results and Discussion 
Method development and optimization 
The main criteria for development of successful UPLC method for determination of QUE in 
tablets were: the method should be able to determine assay of drug in single run and 
should be accurate, reproducible, robust, stability indicating, free of interference from 
blank / placebo / impurities / degradation products and straightforward enough for routine 
use in quality control laboratory. 
The spiked solution of related compounds (N-Oxide, S-Oxide, Que-IV, Des-E, Dimer) and 
QUE were subjected to separation by RP-UPLC. The Rasayan Journal of Chemistry [6] 
literature for QUE states a RP-HPLC method using C18 column for its related substances. 
The mobile phase was containing a gradient mixture of Solvent-A (5mM of ammonium 
acetate) and Solvent-B (acetonitrile) [6]. The separation of all compounds form QUE was 
studied using this composition on UPLC column (Acquity BEH C18 50 x 2.1 mm, 1.7µm)   Development and Validation of a Stability Indicating RP-UPLC Method for Determination of …  101 
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and Waters (UPLC) system with the linear gradient program (Table 1). The flow rate of 0.5 
mL/min was selected with regards to the backpressure and analysis time as well. When 
studied was performed with above condition we observed that N-Oxide and S-Oxide was 
co-eluting and Des-E and QUE were found co-eluting next to them. Que-IV is well 
separated from QUE and Dimer was relatively retained for longer time and it was well 
separated from peak of QUE. Based on this experiment Des-E and QUE was selected as 
a critical pair for separation. During this study column oven temperature was capped 40°C. 
Various types of solvents A and B were studied to optimize the method, which were 
summarized in Table 2 with the observation. Based on above solvent selection 
experimental study optimized UPLC parameters were; flow rate 0.5mL/min; column oven 
temperature 40°C; gradient solvent program as per Table 1; as a Solvent-A 0.1 % 
aqueous triethylamine (adjusted to pH 7.2 with orthophosphoric acid) and as Solvent-B 
mixture of acetonitrile and methanol in the ratio of 80:20 (v/v) respectively.  
Tab. 1.  Gradients program for elution 
Time (min)  Flow rate (mL/min)  % Solvent-A %  Solvent-B Gradient  curve 
Initial 0.5  70 30  Isocratic 
0.5 0.5  70  30  Isocratic 
3.0 0.5  5  95  Linear 
4.0 0.5  5  95  Isocratic 
4.1 0.5  70  30  Isocratic 
5.0 0.5  70  30  Equilibration 
 
Tab. 2.  Summary of solvent used to optimize the method  
Solvent-A (Sol-A)  Solvent-B (Sol-B) Observation/Remarks 
5 mM Ammonium acetate 
solution  Acetonitrile  Co-eluting peak of Des-E and QUE 
was observed 
0.1 % aqueous 
triethylamine  Acetonitrile  Co-eluting peak of Des-E and QUE 
was observed 
0.1 % aqueous 
triethylamine (adjusted to 
pH 7.2 with H3PO4) 
Mixture of acetonitrile 
and water in the ratio of 
90:10 (v/v) 
Poor resolution between Des-E and 
QUE, and higher peak tailing for the 
peak of QUE were observed. 
0.1 % aqueous 
triethylamine (adjusted to 
pH 7.2 with H3PO4) 
Mixture of acetonitrile 
and methanol in the 
ratio of 80:20 (v/v) 
1.3 USP resolution was observed 
between Des-E and QUE 
 
In order to achieve symmetrical peak of QUE and more resolution between Des-E and 
QUE, various stationary phases like C8 (different dimension), C18 (different brand), phenyl 
were also studied. Summary of stationary phases are presented in Table 3. Based on this 
summary it was concluded that Eclipse Plus C18; RRHD (50 x 2.1mm, 1.8µm) giving a 
better resolution (Des-E and QUE) and symmetrical peaks of all component with respect to 
other stationary phases and other equivalent columns. Column oven temperature is also 
studied (at room temperature and 40°C) and found that 40°C temperature is more 
appropriate with respect to resolution and peak shape. The wavelength of QUE maximum 102  R. K. Trivedi and M. C. Patel:   
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(252 nm) was used to have good detection of QUE and impurities (at 2.5 % of standard 
concentration). QUE and their impurities were well resolved in reasonable time of 5 
minutes which was presented in Figure 2 (spiked chromatogram of QUE along with 
impurities). There was no any interference of excipients (placebo) and blank (diluent) at 
the retention time of QUE peak. Overlay chromatograms of blank, placebo and standard 
solution is presented in Figure 3.  
Tab. 3.  Summary of stationary phase used to optimize the method  
Stationary phase  Dimension Observation/Remarks 
Acquity BEH C8  (50 x 2.1) mm, 1.7 µm  Poor resolution between Des-E and QUE 
Acquity BEH C8  (100 x 2.1) mm, 1.7 µm  Poor resolution between Des-E and QUE 
Acquity BEH Phenyl  (50 x 2.1) mm, 1.7 µm  Peak merging of Des-E and QUE 
Acquity BEH C18  (50 x 2.1) mm, 1.7 µm  Poor resolution between Des-E and QUE 
Eclipse Plus C18,  
RRHD  (50 x 2.1) mm, 1.8 µm  Satisfactory resolution between Des-E  
and QUE 
 
Analytical parameters and validation 
After satisfactory development of method it was subjected to method validation as per ICH 
guideline [27]. The method was validated to demonstrate that it is suitable for its intended 
purpose by the standard procedure to evaluate adequate validation characteristics (system 
suitability, accuracy, precision, linearity, robustness, solution stability, filter compatibility 
and stability indicating capability).  
 
Fig. 2.  Spiked chromatogram of QUE along with impurities  
System suitability  
System suitability parameters were measured so as to verify the system, method and 
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replicate injections (standard preparation) was below 0.4 %. Low values of % RSD of 
replicate injections indicate that the system is precise. Results of other system suitability 
parameters such as resolution, theoretical plates, tailing factor, capacity factor and 
similarity factor (between two standard preparations) are presented in Table 4. As seen 
from this data, the acceptable system suitability parameters would be: resolution between 
Des-E and QUE is not less than 1.5, theoretical plates for QUE is not less than 30000, 
tailing factor for QUE is not more than 2.0, similarity factor (between two standard 
preparations) is not less than 0.98 and not more than 1.02 and % RSD of replicate 
injections is not more than 2.0 %. Results of system suitability parameters from different 
studies are also presented in Table 4. Spiked chromatogram of impurity / degradation 
products with QUE is presented in Figure 2. 
Tab. 4.  System suitability results (precision, intermediate precision and robustness) 
Parameter 
Resolution 
between 
Des-E and 
QUE 
Theoretical 
plates for 
QUE 
Tailing 
factor 
for QUE
Capacity 
factor for 
QUE 
Standard 
Similarity 
factor 
% RSD* of 
Standard 
Area 
Precision 1.61  38771  1.50 6.95  1.01  0.31 
Intermediate 
Precision  1.64 38213  1.48  6.97  0.99  0.27 
At 0.45 
mL/min  
flow rate 
1.52 35191  1.55  7.27  0.99  0.35 
At 0.55 
mL/min  
flow rate 
1.72 40663  1.44  6.65  1.00  0.21 
At 37°C 
Column temp.  1.61 37611  1.50  6.94  1.01  0.28 
At 43°C 
Column temp.  1.62 38781  1.47  6.91  1.00  0.20 
Sol-B [−10 % 
methanol]  1.61 37807  1.47  6.92  0.99  0.34 
Sol-B [+10 % 
methanol]  1.60 37972  1.48  6.90  1.01  0.22 
* Determined on six values. 
 
Specificity 
Specificity is the ability of the method to measure the analyte response in the presence of 
its potential impurities [26]. Forced degradation studies were performed to demonstrate 
selectivity and stability indicating capability of the proposed RP-UPLC method. Figure 2 
and 3 are shows that there is no any interferences at the RT (retention time) of QUE due 
to blank, placebo, impurities and degradation products. Significant degradation was not 
observed when QUE was subjected to acid, alkali, thermal, hydrolytic and UV conditions. 
Significant degradation was observed when the drug product was subjected to oxidative 
hydrolysis (30% H2O2, 60°C, 1h) leading to the formation of N-Oxide and S-Oxide. Overlay 
chromatograms (blank, placebo and sample) of peroxide degradation study are presented 
in Figure 4A along with QUE purity plot (Figure 4B). Peak due to QUE was investigated for 104  R. K. Trivedi and M. C. Patel:   
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spectral purity in the chromatogram of all exposed samples and found spectrally pure. The 
purity and assay of QUE was unaffected by the presence of its impurities and degradation 
products and thus confirms the stability-indicating power of the developed method. Results 
from forced degradation study are given in Table 5.  
Tab. 5.  Summary of forced degradation results  
Degradation condition  Assay 
(% w/w)
Purity 
Flag 
Major degradation 
products* 
Control sample  99.9  No  N.A. 
Acidic hydrolysis (1N HCl, 60°C, 1 h)  99.2  No  No significant degradation 
observed 
Alkaline hydrolysis (1N NaOH, 60°C, 1 h) 98.8  No No  significant degradation 
observed 
Oxidation (30% H2O2, 60°C, 1 h)  90.0  No  N-Oxide (4.25 %)* and  
S-Oxide (4.68 %)* 
Water hydrolysis (60°C, 24 h)  99.5  No  No degradation observed 
Thermal (60°C, 6 h) solid  100.1  No  No degradation observed 
Exposed to UV at 254nm   100.3  No  No degradation observed 
* Percentage area against quetiapine; N.A. Not applicable. 
 
 
 
Fig. 3.  Overlay chromatograms of blank (bottom), placebo (middle) and standard (top) 
preparation 
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Fig. 4A.  Overlay chromatograms of peroxide degradation study [blank (bottom), placebo 
(middle) and degraded sample (top)]  
 
Fig. 4B.  Quetiapine peroxide degraded sample purity plot  
Precision  
The precision of the assay method was verified by repeatability and by intermediate 
precision. Precision was investigated using sample preparation procedure for six real 
samples of tablets and analyzing by proposed method. Intermediate precision was studied 
using different column, and performing the analysis on different day. The average % assay 
(n=6) of QUE was 99.9 with RSD of 0.38 %. Results are presented in Table 6 along with 
intermediate precision data. Low values of % RSD, indicates that the method is precise.  
Tab. 6.  Precision and Intermediate precision results 
Precision at 100 %  Intermediate precision 
% Assay 
# % RSD* % Assay 
# %  RSD*  Quetiapine 
99.9 0.38  100.2  0.39 
# Average of six determinations; * Determined on six values. 106  R. K. Trivedi and M. C. Patel:   
Sci Pharm. 2011; 79: 97–111 
Accuracy 
To confirm the accuracy of the proposed method, recovery experiments were carried out 
by standard addition technique. Five different levels (50 %, 75 %, 100 %, 125 % and 150 
%) of standards were added to pre-analyzed placebo samples in triplicate. The percentage 
recoveries of QUE at each level and each replicate were determined. The mean of 
percentage recoveries (n =15) and the % RSD was calculated. The amount recovered was 
within ±1 % of amount added, which indicates that the method is accurate and also there 
is no interference due to excipients present in tablets. The results of recoveries for assay 
are shown in Table 7.  
Tab. 7.  Accuracy results 
Quetiapine  At 50 %  At 75 % At 100 % At 125 % At 150 % 
% Recovery 
#  99.4  99.8 99.7 100.0 99.3 
% R.S.D.*  0.40  0.35  0.25 0.26 0.20 
* Determined on three values; 
# Mean of three determinations. 
 
Linearity 
Linearity was demonstrated from 50 % to 150 % of standard concentration using minimum 
five calibration levels (50 %, 75 %, 100 %, 125 % and 150 %) for the QUE compound, 
which gave us a good confidence on analytical method with respect to linear range. The 
response was found linear for QUE from 50 % to 150 % of standard concentration and 
correlation coefficient was also found greater than 0.9999. Y-intercept bias was also found 
within ± 2. The result of Correlation coefficients, Y-intercept bias and linearity equations for 
QUE are presented in Table 8. Linearity curve is presented in Figure 5. 
Tab. 8.  Linearity results  
Linearity range 
(µg/mL) 
Correlation 
Coefficient (r
2) Linearity (Equation)  Y-intercept bias
62.5 to 187.5  0.99993  y = 3955.2943(x) − 4182.2 −1.865 
 
 
Fig. 5.  Linearity curve    Development and Validation of a Stability Indicating RP-UPLC Method for Determination of …  107 
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Robustness  
The robustness as a measure of method capacity to remain unaffected by small, but 
deliberate changes in chromatographic conditions was studies by testing influence of small 
changes in flow rate (± 0.05 mL/min), change in column oven temperature (± 3°C) and 
change in Sol-B (± 10 % of methanol composition). No significant effect was observed on 
system suitability parameters such as resolution, theoretical plates, tailing factor, capacity 
factor, similarity factor and % RSD of QUE, when small but deliberate changes were made 
to chromatographic conditions. The results are presented in Table 4 along with system 
suitability parameters of precision and intermediate precision study. Thus, the method was 
found to be robust with respect to variability in above conditions. 
Stability of sample solution 
Stability of sample solution was established by storage of sample solution at ambient 
temperature for 24 h. QUE sample solution was re-analyzed after 12 and 24 h time 
intervals and assay was determined and compared against fresh sample. Sample solution 
did not show any appreciable change in assay value when stored at ambient temperature 
up to 24 h, which are presented in Table 9. The results from solution stability experiments 
confirmed that sample solution was stable for up to 24 h during assay determination.  
Tab. 9.  Solution stability results 
Initial  After 12 hrs.  After 24 hrs.  % Assay  
100.1 99.9  99.8 
 
Filter compatibility 
Filter compatibility was performed for nylon 0.2 µm syringe filter (Pall Life sciences) and 
PVDF 0.2 µm syringe filter (Millipore). To confirm the filter compatibility in proposed 
method, filtration recovery experiment was carried out by sample filtration technique. 
Sample was filtered through both syringe filter and percentage assay was determined and 
compared against centrifuged sample. Sample solution was not showing any significant 
changes in assay percentage with respect to centrifuged sample. Percentage assay 
results are presented in Table 10. In displayed result difference in % assay was not 
observed more than ±0.2, which indicates that both syringe filters having a good 
compatibility with sample solution. 
Tab. 10.  Filter compatibility results 
Centrifuged  PVDF Syringe filter 
0.2µm (Millipore) 
Nylon Syringe filter 0.2µm 
(Pall Life Sciences)  % Assay 
99.9 100.1  99.8 
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Experimental 
Materials and Reagents 
Tablets and standard of Quetiapine Fumarate (99.5 %) and its five impurities namely N-
oxide (98.1 %), S-oxide (98.5 %), Que-IV (99.2 %), Des-ethanol (96.8 %) and Dimmer 
(98.4 %) were provided by Dr. Reddy’s laboratories Ltd., Hyderabad, India. HPLC grade 
acetonitrile and methanol were obtained from J.T.Baker (NJ., USA). GR grade 
orhtophosphoric acid and GR grade triethylamine were obtained from Merck Ltd. (Mumbai, 
India). 0.2 µm nylon membrane filter and nylon syringe filters were purchased from Pall life 
science limited (India). 0.2 µm PVDF syringe filter was purchased from Millipore (India). 
High purity water was generated by using Milli-Q Plus water purification system (Millipore, 
Milford, MA, USA).  
Equipments 
Cintex digital water bath was used for specificity study. Photo stability studies were carried 
out in a photo-stability chamber (Sanyo, Leicestershire, UK). Thermal stability studies were 
performed in a dry air oven (Cintex, Mumbai, India). 
Chromatographic conditions 
Analyses were performed on Acquity UPLC system (Waters, Milford, USA), consisting of a 
binary solvent manager, sample manager and PDA (photo diode array) detector. System 
control, data collection and data processing were accomplished using Waters Empower-2 
chromatography data software. The chromatographic condition was optimized using 
Agilent Eclipse Plus C18, RRHD  1.8 µm (50 mm x 2.1 mm) column. 0.1% aqueous 
triethylamine (adjusted to pH 7.2 with orthophosphoric acid) was used as a solvent-A and 
mixture of acetonitrile and methanol in the ratio of 80:20 (v/v) respectively was used as 
solvent-B. Solvents-A and B was filtered through 0.2 µm nylon membrane filter and 
degassed under vacuum prior to use. The separation of QUE and impurities was achieved 
by gradient elution using Sol-A and Sol-B. Mixture of water, acetonitrile and perchloric acid 
in the ratio of 200:800:0.13 (v/v/v) respectively was used as a diluent. The finally selected 
and optimized conditions were as follows: injection volume 1 µL, gradient elution (Table 1), 
at a flow rate of 0.5 mL/min at 40°C (column oven) temperature, detection wavelength 252 
nm. The stress degraded samples and the solution stability samples were analyzed using 
a PDA detector covering the range of 200-400nm.  
System suitability solution preparation 
System suitability solution was prepared by dissolving standard substance and impurity in 
diluent to obtain solution containing 3 µg/mL of Des-E and 125 µg/mL of QUE.  
Standard solution preparation  
Standard solution was prepared by dissolving standard substance in diluent to obtain 
solution containing 125 µg/mL of QUE. 
Sample solution preparation 
Twenty tablets were crushed to fine powder. An accurately weighed portion of the powder 
equivalent to 25 mg of QUE was taken into 200 mL volumetric flask. About 150 mL of 
diluent was added to this volumetric flask and sonicated in an ultrasonic bath for 10 min.   Development and Validation of a Stability Indicating RP-UPLC Method for Determination of …  109 
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This solution was then diluted up to the mark with diluent and mixed well. It was then 
filtered through 0.2 µm PVDF syringe filter and the filtrate was collected after discarding 
first few milliliters. 
Conclusion 
A gradient RP-UPLC method was successfully developed for the estimation of quetiapine 
in pharmaceutical dosage form. The method validation results have proved that the 
method is selective, precise, accurate, linear, robust, filter compatible and stability 
indicating. The run time (5.0 min) enables for rapid determination of drug. Moreover, it may 
be applied for determination of QUE in the study of blend uniformity, tablet content 
uniformity and in-vitro dissolution profiling of QUE dosage forms, where sample load is 
higher and high throughput is essential for faster delivery of results. 
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